strong execut balanc lt
continu execut well includ deliv solid
humira imbruvica growth pipelin progress howev
lower pt due grow humira headwind
expect constrain multipl maintain ew
tweak ep estim lower pt bump ep
heel strong perform reduc
slightli lower gm previous assum much
benefit humira royalti payment reduct lower pt
old ep new expect
grow financi percept pressur franchis humira pt
base case ep peer mean due risk long-term
biosimilar set launch europ oct management state
call late april compani estim declin ex-u humira
rel call juli manag point
fact market go biosimilar time project
base bottoms-up forecast howev manag adjust
appropri base result cautiou model
forecast ex-u humira declin
us humira continu grow expect materi
declin biosimilar launch us humira sale grew yoy
includ high-singl digit volum growth price model us
humira grow call ceo
gonzalez state compani long-rang plan assumpt
least one interchang biosimilar year multipl interchang
biosimilar year beyond said compet price
competit environ maintain vast major volum project
declin us humira rapid declin later year
upadacitinib jak select-earli dvt/pe safeti data patient
major pharmaceut unit state america
unless otherwis note metric base modelwar
consensu data provid thomson reuter estim
seek busi
compani cover morgan stanley research
result investor awar firm may
conflict interest could affect object
morgan stanley research investor consid
morgan stanley research singl factor make
invest decis
analyst certif import disclosur
refer disclosur section locat end
elagolix hormon add-back uterin fibroid detail data
file
file upadacitinib ra
potenti note ask possibl major
transact ceo gonzalez respond call today lot
asset opinion either valuat standpoint get
right return fit strateg
pt base base case ep
peer mean risk long-term humira declin next decad
bull case ep
bull case ep
sale surpass expect gross margin forecast due declin
humira royalti payment drive ep project pipelin
add new revenu driver diversifi beyond humira help price-to-earnings
base case ep
base case ep
see balanc risk-reward expect strong ep growth posit
pipelin develop near-term balanc long-term humira biosimilar
threat includ risk us biosimilar interchang could
bear case ep
bear case ep
earn forecast newsflow concern humira imbruvica
sale disappoint caus ep forecast pipelin candid
disappoint jak due blood clot risk biosimilar humira threat includ
neg patent challeng news interchang progress caus concern
equal-weight share
ep growth
growth near-medium term
balanc risk price-to-earnings contract long term
us biosimilar humira entri approach
like pursu extern
transact enhanc pipelin
surpris neg us humira price
financi result rel expect
humira imbruvica sale trends/outlook
clinic trial result potenti btk
competitor imbruvica
extern busi develop
risk achiev price
upsid risk result
posit humira patent news value-
downsid risk result
disappoint problemat legal
biosimilar impact remicad enbrel ex-u
first remicad biosimilar launch first
enbrel biosimilar launch
exhibit remicad enbrel ex-u sale declin yoy sinc biosimilar enter figur
adjust fx impact
price
price
exhibit trade mean year histor mean
price data
price data
exhibit incom statement margin analysi valuat
sg sale
 sale
exhibit balanc sheet statement
short-term invest
a/p accru liabil
total liabil s/e
chang work capit
oper
invest
net chang debt
financ
net chang cash
